2580154-02-3
Chemical Structure
Certepetide
Synonym(s): CEND-1; iRGD; LSTA1
- CAS No.: 2580154-02-3
- Formula:C37H60N14O14S2
- Molecular Weight:989.09
InChIKey: YPHPUVJQSYACEN-HUVRVWIJSA-N
SMILES: O=C1[C@@]2([H])N(C(CNC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@H](CSSC[C@H](NC([C@@H](N1)CC(O)=O)=O)C(N)=O)NC(C)=O)=O)CCCNC(N)=N)=O)=O)CC(O)=O)=O)CCCCN)=O)=O)CCC2
Biological Activity: Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Certepetide | 99.80% | Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 36, No. 2, 2022
- [2]. Ruoslahti Erkki, et al. Methods for treating pancreatic cancer and other solid tumors. WO2021226148.
- [3]. Andrew Peter Dean, et al. Updated single institution outcome data from the first-in-human CEND-1 trial in metastatic pancreatic cancer. Journal of Clinical Oncology 2021 39:15_suppl, e16274-e16274
